速递丨已达成超10亿美元合作，维立志博自免1类新药在中国获批临床

医药观澜11-27

中国国家药监局药品审评中心（CDE）官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。公开资料显示，这是一款新型抗BDCA2/TACI双特异性融合蛋白。LBL-047是维立志博的临床前管线，是将工程化改造的跨膜激活剂及钙调亲环素配体相互作用分子（TACI）结构域和去岩藻糖的抗血液树突状细胞抗原2（BDCA2）人源化单克隆抗体融合，得到的抗BDCA2/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2586214365?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-27 11:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2586214365","market":"hk","top_or_hot":-1,"title":"速递丨已达成超10亿美元合作，维立志博自免1类新药在中国获批临床","media":"医药观澜","content":"<div>\n<p>中国国家药监局药品审评中心（CDE）官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。公开资料显示，这是一款新型抗BDCA2/TACI双特异性融合蛋白。LBL-047是维立志博的临床前管线，是将工程化改造的跨膜激活剂及钙调亲环素配体相互作用分子（TACI）结构域和去岩藻糖的抗血液树突状细胞抗原2（BDCA2）人源化单克隆抗体融合，得到的抗BDCA2/...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速递丨已达成超10亿美元合作，维立志博自免1类新药在中国获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速递丨已达成超10亿美元合作，维立志博自免1类新药在中国获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-27 11:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b><strong>医药观澜</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国国家药监局药品审评中心（CDE）官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。公开资料显示，这是一款新型抗BDCA2/TACI双特异性融合蛋白。LBL-047是维立志博的临床前管线，是将工程化改造的跨膜激活剂及钙调亲环素配体相互作用分子（TACI）结构域和去岩藻糖的抗血液树突状细胞抗原2（BDCA2）人源化单克隆抗体融合，得到的抗BDCA2/...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","article_id":"2586214365","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127122026a7145b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586214365","pubTimestamp":1764214913,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中国国家药监局药品审评中心官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","BK1161":"生物科技","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","09887":"维立志博-B"},"translate_title":"Express | A cooperation of over US $1 billion has been reached, and Weili Zhibo's self-immune Class 1 new drug has been approved for clinical use in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1.5},"content_text":"中国国家药监局药品审评中心（CDE）官网公示，维立志博生物申报的1类新药注射用LBL-047获批临床，拟开发治疗系统性红斑狼疮。公开资料显示，这是一款新型抗BDCA2/TACI双特异性融合蛋白。LBL-047是维立志博的临床前管线，是将工程化改造的跨膜激活剂及钙调亲环素配体相互作用分子（TACI）结构域和去岩藻糖的抗血液树突状细胞抗原2（BDCA2）人源化单克隆抗体融合，得到的抗BDCA2/TACI长效双特异抗体融合蛋白，并通过引入了YTE突变以进一步延长抗体的半衰期，降低给药频次，提高患者依从性。TACI是B细胞活化因子（BAFF）和增殖诱导配体（APRIL）的天然受体，而BAFF和APRIL是促进B细胞和浆细胞存活、成熟和发挥功能的关键细胞因子。BDCA2在浆细胞样树突状细胞（pDCs）细胞膜上特异性表达，抗BDCA2抗体可以通过结合BDCA2传递下游信号，直接抑制干扰素的产生。B细胞和pDC在许多自身免疫性疾病的发病机制中起到关键和协同的作用，抑制B细胞和pDC功能是治疗多种自免疾病的潜在策略。根据维立志博公开资料介绍，LBL-047的设计通过选择性清除pDCs以降低I型干扰素（IFN-I）生成，同时抑制BAFF/APRIL信号通路来阻断B细胞活化、存活及抗体产生。通过靶向自身免疫疾病发病机制中的两个关键驱动因素，这一差异化策略有望覆盖多种自身免疫适应症。值得一提的是，今年10月，维立志博宣布与Dianthus Therapeutics达成独家全球合作伙伴关系，共同推进LBL-047。维立志博将授予Dianthus在大中华区以外独家研发、生产及商业化LBL-047的权益，获得最高3800万美元的首付款及近期里程碑付款，其中包括2000万美元首付款、2025年第四季度支付的500万美元，以及最高1300万美元的潜在近期里程碑付款。该交易总金额（含临床开发、监管及商业化里程碑）最高可达10亿美元。参考资料：[1]维立志博与Dianthus Therapeutics签订全球独家许可协议，共同推进潜在全球首创及同类最优自免产品LBL-047.From https://mp.weixin.qq.com/s/goq4H9KozAnkNDnxumkVkg[2]登上2024 EULAR口头报告！维立志博全球首创抗BDCA2/TACI长效双特异抗体融合蛋白LBL-047临床前数据公布.Fromhttps://mp.weixin.qq.com/s/v_4pktmF1KQQUYqS3J8P_g","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586214365","isCrawlerRequest":true}